Indications and uses
Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT* (carbachol intraocular solution, USP) 0.01% reduces the intensity of IOP elevation in the first 24 hours after cataract surgery.
Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT* (carbachol intraocular solution, USP) 0.01% reduces the intensity of IOP elevation in the first 24 hours after cataract surgery.
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled ...
MIOSTAT™ (carbachol intraocular solution, USP) 0.01% is a sterile balanced salt solution of carbachol for intraocular injection. The active ingredient is represented by the chemical structure:

Established Name: Carbachol
Chemical Name: Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,Ntrimethyl-, chloride.
Molecular Formula: C6H15CIN2O2
Molecular Weight: 182.65
Each mL of MIOSTAT™ (carbachol intraocular solution, USP) 0.01%contains: Active: carbachol 0.01%.
Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dehydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and Water for Injection. pH range is 6.5-7.5.
Carbachol is a potent cholinergic (parasympathomimetic) agent which produces constriction of the iris and ciliary body resulting in reduction in intraocular pressure (IOP). The exact mechanism by which carbachol lowers IOP is not precisely known.
Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT* (carbachol intraocular solution, USP) 0.01% reduces the intensity of IOP elevation in the first 24 hours after cataract surgery.
Should not be used in those persons showing hypersensitivity to any of the components of this preparation.
For single-dose intraocular use only. Discard unused portion. Intraocular carbachol 0.01% should be used with caution in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. spasm, urinary tract obstruction and Parkinson's disease. The vial stopper contains natural rubber (latex) which may cause severe allergic reactions.
Use only if the container is undamaged.
Studies in animals to evaluate the carcinogenic potential have not been conducted.
There are no adequate and well-controlled studies in pregnant women. MIOSTAT* (carbachol intraocular solution, USP) 0.01% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known if this medication is excreted in breast milk. Exercise caution when administering to a nursing woman.
Safety and efficacy in pediatric patients have not been established.
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Ocular: Corneal clouding, persistent bullous keratopathy, retinal detachment and postoperative iritis following cataract extraction have been reported.
Systemic: Side effects such as flushing, sweating, epigastric distress, abdominal cramps, tightness in urinary bladder, and headache have been reported with topical or systemic application of carbachol.
The following additional reactions have been identified during post-approval use of MIOSTAT (carbachol intraocular solution, USP) 0.01% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to MIOSTAT, or a combination of these factors, include: corneal edema, drug effect prolonged (miosis), eye inflammation, eye pain, intraocular pressure increased, ocular hyperemia, vision blurred, visual impairment, and vomiting.
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
In a 2.0 mL glass vial with a 1.5 mL fill, grey butyl stopper and aluminum seal packaged twelve to a carton…………………………………………………………………………..NDC 0065-0023-15
STORAGE: Store at 15° - 30°C (59° - 86°F).
© 2021 Alcon Inc.
Distributed by:
Alcon Laboratories, Inc.
Fort Worth, Texas 76134
300048977-0621
NDC 0065-0023-15
MIOSTAT™
(CARBACHOL INTRAOCULAR
SOLUTION, USP) 0.01%
TWELVE
1.5 mL Sterile Glass Vials
Alcon Laboratories, Inc., Fort Worth, Texas 76134 USA
Alcon
USUAL DOSAGE: 0.5 mL
STORAGE: Store at 15 - 30C (59 - 86F).
WARNING: For single-dose intraocular use only. Discard unused portion.
Rx Only
INGREDIENTS: A sterile balanced salt solution containing (per mL) Active:
carbachol 0.01%. Inactives: sodium chloride 0.64%, potassium chloride
0.075%, calcium chloride dihydrate 0.048%, magnesium chloride
hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate
dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust
pH) and water for injection.
GTIN: 10300650023150
S/N:
LOT:
EXP.:
300048975-0621

NDC 0065-0023-15
MIOSTAT*
(CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%
TWELVE
1.5 mL Sterile Glass Vials
Alcon Laboratories, Inc., Fort Worth, Texas 76134 USA
* a trademark of Novartis
©2004, 2013, 2015 Novartis
Alcon
®
a Novartis company
USUAL DOSAGE: 0.5 mL
STORAGE: Store at 15 - 30C (59 - 86F).
Rx Only
INGREDIENTS: A sterile balanced salt solution containing (per mL) Active: carbachol 0.01%. Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dihydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection.
GTIN: 10300650023150
S/N
LOT:
EXP.:
9011781-0415

MIOSTAT™
(carbachol intraocular solution, USP) 0.01%
Alcon
300056865
LOT: EXP.:

MIOSTAT®
(carbachol intraocular solution, USP) 0.01%
Alcon®
© 2001, 2018 Alcon, Inc.
H15348-0718
LOT: EXP.:

LOT: EXP: 305190-1104
NDC 0065-0023-15
MIOSTAT®
(CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01% 1.5mL
Rx Only. Sterile Unless Package Open or Damaged Read enclosed insert. INGREDIENTS:
Active: carbachol 0.01%. Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dihydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection. USUAL DOSAGE: 0.5mL STORAGE: Store at 15° - 30°C (59° - 86°F).
©2004 Alcon, Inc. Alcon Labs., Inc. Fort Worth, TX. 76134

| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 308966 | carbachol 0.01 % in 1.5 ML Intraocular Injection | PSN | 12 |
| 991606 | MIOSTAT 0.01 % in 1.5 ML Intraocular Injection | PSN | 12 |
| 991606 | 1.5 ML carbachol 0.1 MG/ML Injection [Miostat] | SBD | 12 |
| 308966 | 1.5 ML carbachol 0.1 MG/ML Injection | SCD | 12 |
| 991606 | 1.5 ML Miostat 0.1 MG/ML Injection | SY | 12 |
| 308966 | carbachol 0.01 % per 1.5 ML Intraocular Injection | SY | 12 |
| 991606 | Miostat 0.01 % per 1.5 ML Intraocular Injection | SY | 12 |
| Class | Version | Type | Effective |
|---|---|---|---|
| CARBAMOYLCHOLINE Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0065-0023-15 | MIOSTAT | 1.5 mL in 1 VIAL, GLASS | SOLUTION | 1.5 | 12 | |
| 0065-0023-15 | MIOSTAT | 12 in 1 CARTON | SOLUTION | 12 | 12 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0065-0023-15 | ML - Milliliter | 0065-0023 | 5bf22fcb-4cb8-405e-89e8-b687e3b6a35b | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CARBACHOL | ACTIVE INGREDIENT | 8Y164V895Y | 3 | |
| CARBACHOL | ACTIVE MOIETY | 8Y164V895Y | 3 | |
| CALCIUM CHLORIDE | INACTIVE INGREDIENT | M4I0D6VV5M | 3 | |
| HYDROCHLORIC ACID | INACTIVE INGREDIENT | QTT17582CB | 3 | |
| MAGNESIUM CHLORIDE | INACTIVE INGREDIENT | 02F3473H9O | 3 | |
| POTASSIUM CHLORIDE | INACTIVE INGREDIENT | 660YQ98I10 | 3 | |
| SODIUM ACETATE | INACTIVE INGREDIENT | 4550K0SC9B | 3 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 3 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 3 | |
| TRISODIUM CITRATE DIHYDRATE | INACTIVE INGREDIENT | B22547B95K | 3 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0065-0023 | 0065-0023-15 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CARBACHOL | 8Y164V895Y | ACTIB |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| POTASSIUM CHLORIDE | 660YQ98I10 | IACT |
| CALCIUM CHLORIDE | M4I0D6VV5M | IACT |
| MAGNESIUM CHLORIDE | 02F3473H9O | IACT |
| SODIUM ACETATE | 4550K0SC9B | IACT |
| TRISODIUM CITRATE DIHYDRATE | B22547B95K | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | SOLUTION / OPHTHALMIC | 2 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / OPHTHALMIC | 0.31 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / OPHTHALMIC | 13 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / OPHTHALMIC | 0.05 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / OPHTHALMIC | 0.05 %w/v | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SOLUTION / OPHTHALMIC | 0.22 %w/v | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | SOLUTION / OPHTHALMIC | 1 mg | ||
| MAGNESIUM CHLORIDE | MAGNESIUM CHLORIDE | 02F3473H9O | SOLUTION / OPHTHALMIC | 0.01 %w/v | ||
| TRISODIUM CITRATE DIHYDRATE | TRISODIUM CITRATE DIHYDRATE | B22547B95K | SOLUTION / OPHTHALMIC | 0.45 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / OPHTHALMIC | 0.31 %w/v | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SOLUTION / OPHTHALMIC | 0.22 %w/v | ||
| MAGNESIUM CHLORIDE | MAGNESIUM CHLORIDE | 02F3473H9O | SOLUTION / OPHTHALMIC | 0.01 %w/v | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | SOLUTION / OPHTHALMIC | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / OPHTHALMIC | 13 mg | ||
| TRISODIUM CITRATE DIHYDRATE | TRISODIUM CITRATE DIHYDRATE | B22547B95K | SOLUTION / OPHTHALMIC | 0.45 %w/v | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | SOLUTION / OPHTHALMIC | 2 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N016968-001 | MIOSTAT | CARBACHOL | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | N016968-001 | MIOSTAT | 0.01% | SOLUTION / INTRAOCULAR | RLD, RS, Approved before 1982 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| MIOSTAT | CARBACHOL | Alcon Laboratories, Inc. | f28d7a56-e079-4a8b-ad81-9a97c780de67 | 2023-02-10 | Warnings, Adverse reactions | 0065-0023-15 0065-0023 00065002315 a76a34d0-2e07-408d-a8c8-d00f2715cad7 f28d7a56-e079-4a8b-ad81-9a97c780de67 |
Adverse event summaries are temporarily unavailable. Other product information remains available.